When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SNDX - Syndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemia
Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals (NASDAQ:SNDX) announces that the European Commission has granted Orphan Drug Designation to SNDX-5613, an oral menin inhibitor, for the treatment of acute myeloid leukemia (AML). Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, protocol assistance, reduced regulatory, if approved. In June, SNDX-5613 was granted FDA Fast Track status for treatment of leukemia.